Last reviewed · How we verify
EHSG-KF
The specific mechanism of action for EHSG-KF is not publicly disclosed.
At a glance
| Generic name | EHSG-KF |
|---|---|
| Also known as | denovoSkin |
| Sponsor | CUTISS AG |
| Modality | Biologic |
| Phase | Phase 2 |
Mechanism of action
As the mechanism of action is not specified, it is unclear how EHSG-KF interacts with biological processes or targets within the body.
Approved indications
Common side effects
Key clinical trials
- Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents (PHASE2)
- Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children (PHASE2)
- Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children (PHASE2)
- Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EHSG-KF CI brief — competitive landscape report
- EHSG-KF updates RSS · CI watch RSS
- CUTISS AG portfolio CI